姬芳玲
Associate Professor Supervisor of Doctorate Candidates Supervisor of Master's Candidates
Gender:Female
Alma Mater:大连理工大学
Degree:Doctoral Degree
School/Department:生物工程学院
Discipline:Bioengineering
Business Address:生物工程学院547房间
E-Mail:fanglingji@dlut.edu.cn
Hits:
Indexed by:Journal Papers
Date of Publication:2016-12-15
Journal:PHYTOMEDICINE
Included Journals:SCIE、PubMed、Scopus
Volume:23
Issue:14
Page Number:1778-1786
ISSN No.:0944-7113
Key Words:Baicalein; 10-hydroxy camptothecin; Anti-cancer; Topoisomerase I; p53; Apoptosis
Abstract:Background: 10-Hydroxy camptothecin (HCPT), a naturally occurring alkaloid, is a clinical drug for cancer chemotherapy. Baicalein (BA) is a flavonoid extracted from the root of Scutellaria baicalensis. The synergistic anti-cancer effect of BA and HCPT has not been reported.
Purpose: To explore whether and how BA enhances the anti-cancer effect of HCPT in BGC823 cells.
Methods: Cell viability was measured by MTT assay. Apoptosis and cell cycle were analyzed through flow cytometry and western blotting analysis. DNA damage was determined by a comet assay. The activity of topoisomerase I (Topo I) was detected by the plasmid DNA relaxation assay. The synergistic anti-cancer effect of BA and HCPT in vivo was tested by BGC823 xenografted tumor model.
Results: BA at non-toxic doses prominently enhanced the anti-cancer activities of HCPT in BGC823, MCF7 and SMMC7721 cells. Combination treatment of BA and HCPT induced BGC823 cells apoptosis mainly via intrinsic rather than extrinsic pathways, and preferentially arresting cell cycle in G1 and G2 phases with the aid of p21. Of note, p53, the upstream regulator of cell apoptosis and cycle, was increased by 5 folds in combination group. It helped to further trigger DNA damage and inhibit Topo I catalytic activity after combination treatment of BA and HCPT. Moreover, the BGC823 xenografted tumor growth rate in nude mice was repressed in a greater degree (P < 0.01) in the combinational group than the single-drug group.
Conclusion: HCPT and BA, a new and effective combination therapy, synergistically target Topo I and up-regulate p53 to induce cell apoptosis and cell cycle arrest. (C) 2016 Elsevier GmbH. All rights reserved.
诚邀有志于探索生命科学前沿的优秀学子,携手推动相关领域的科学研究与创新!
本团队现面向对生物工程、生物医用材料、免疫学、生物信息学、生物学及医学研究等领域感兴趣、热爱科学研究的同学,招收硕士和博士研究生。
姬芳玲,工学博士,副教授,博士生导师,国际磁共振学会会员,美国化学会ACS会员,中国生物材料学会血液净化材料分会委员。研究方向为重大疾病(自身免疫性疾病)发生发展机制、(纳米)抗体的结构与功能、淋巴细胞分离及细胞异质性研究。主持国家自然科学基金2项,省部级基金1项,参加国家重点项目1项。研究成果发表在Angew. Chem.、Analytical Chemistry、Acta Biomaterialia 及Bioconjugate Chemistry等国际一流期刊。已授权中国发明专利3项。
2006年本科毕业于大连理工大学,获生物工程工学学士学位。2013年研究生毕业于大连理工大学,获生物化工工学博士学位。攻读博士学位期间,获得国家留学基金委资助,前往美国匹兹堡大学医学部结构生物学系进行博士联合培养,联合培养博士导师:美国国家科学院院士、英国皇家化学学会会士Angela M. Gronenborn 教授。2013年12月入职大连理工大学生命科学与技术学院。荣获2020年全国高校生命科学类微课教学比赛三等奖。辽宁省普通高等教育(本科)教学成果奖二等奖(排名第六)、大连理工大学优秀教育教学成果一等奖(排名第六)。2022年入选辽宁省首届优秀研究生导师团队成员。主译并由高等教育出版社出版Damien Nevoltris和Patrick Chames编著的《抗体工程》(第三版)。指导本科生荣获全国大学生生命科学竞赛二等奖、指导“大学生创新创业训练计划”国家级、省级和校级等项目。
工作及教育经历
2022/12至今,大连理工大学,生物工程学院,博士生导师
2018/12至今,大连理工大学,生物工程学院,副教授
2013/12-2018/11,大连理工大学,生命科学与技术学院,讲师
2013/08-2013/11,大连理工大学,生命科学与技术学院,师资博士后
2010/09-2012/10,美国匹兹堡大学医学部结构生物学系,联合培养博士
2006/09-2013/07,大连理工大学,生物化工专业,博士学位(保研)
2002/09-2006/07,大连理工大学,生物工程专业,学士学位